title: Metastatic dormancy and progression in thyroid cancer: targeting cells in the metastatic frontier.
abstract: BACKGROUND
  Metastatic dormancy, or the ability of cancer cells to survive but not progress in metastatic environments, is now recognized to be a common occurrence in cancer.
  
  
  CONCLUSIONS
  From a clinical perspective, this phenomenon is common in metastatic well-differentiated thyroid cancer, whereby patients often present with distant metastases that remain stable for years after removal of the primary tumor and subsequent treatment. Experimental data suggest that metastases can develop throughout the life of a cancer and that progression in the distant environment depends on the biology of the cancer cells that metastasize as well as that of the various microenvironments they encounter. A firm understanding of how thyroid cancer cell progression is regulated in different metastatic environments is necessary to devise effective therapies targeting progressive metastatic thyroid cancer.
  
  
  CONCLUSIONS
  In this review, current models of metastatic progression and factors that regulate late-stage metastatic progression that are particularly relevant for thyroid cancer are discussed.
authors.affiliation: Divisions of Endocrinology and Oncology, The Ohio State University College of Medicine and Arthur G. James Comprehensive Cancer Center, Columbus, Ohio, USA. matthew.ringel@osumc.edu
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Ringel
mesh_terms: D002986:Clinical Trials as Topic; D018450:Disease Progression; D055354:Exosomes / Q000378:metabolism; D005109:Extracellular Matrix / Q000378:metabolism; D006801:Humans; D007107:Immune System; D008495:Medical Oncology / Q000379:methods; D008954:Models, Biological; D009362:Neoplasm Metastasis; D009389:Neovascularization, Pathologic; D009857:Oncogenes; D013954:Thyroglobulin / Q000378:metabolism; D013964:Thyroid Neoplasms / Q000473:pathology* / Q000628:therapy*
chemical_list: D013954:Thyroglobulin